Mesenchymal Stromal Cells for the Treatment of Interstitial Lung Disease in Children: A Look from Pediatric and Pediatric Surgeon Viewpoints
Open Access
Abstract
Mesenchymal stromal cells (MSCs) have been proposed as a potential therapy to treat congenital and acquired lung diseases. Due to their tissue-regenerative, anti-fibrotic, and immunomodulatory properties, MSCs combined with other therapy or alone could be considered as a new approach for repair and regeneration of the lung during disease progression and/or after post- surgical injury. Children interstitial lung disease (chILD) represent highly heterogeneous rare respiratory diseases, with a wild range of age of onset and disease expression. The chILD is characterized by inflammatory and fibrotic changes of the pulmonary parenchyma, leading to gas exchange impairment and chronic respiratory failure associated with high morbidity and mortality. The therapeutic strategy is mainly based on the use of corticosteroids, hydroxychloroquine, azithromycin, and supportive care; however, the efficacy is variable, and their long-term use is associated with severe toxicity. The role of MSCs as treatment has been proposed in clinical and pre-clinical studies. In this narrative review, we report on the currently available on MSCs treatment as therapeutical strategy in chILD. The progress into the therapy of respiratory disease in children is mandatory to ameliorate the prognosis and to prevent the progression in adult age. Cell therapy may be a future therapy from both a pediatric and pediatric surgeon’s point of view.Keywords
Funding Information
- Fondo integrativo Speciale per la Ricerca Covid-19, Ministero dell'Università e della Ricerca (FISR2020IP_02959)
This publication has 162 references indexed in Scilit:
- MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune ModulationStem Cells International, 2013
- The Pathology of Bleomycin-Induced Fibrosis Is Associated with Loss of Resident Lung Mesenchymal Stem Cells That Regulate Effector T-cell ProliferationStem Cells, 2011
- Bone Marrow Stromal Cells Attenuate Lung Injury in a Murine Model of Neonatal Chronic Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Airway Delivery of Mesenchymal Stem Cells Prevents Arrested Alveolar Growth in Neonatal Lung Injury in RatsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Pulmonary Passage is a Major Obstacle for Intravenous Stem Cell Delivery: The Pulmonary First-Pass EffectStem Cells and Development, 2009
- Diffuse Lung Disease in Young ChildrenAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Bronchopulmonary DysplasiaAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cellsNature Cell Biology, 2007
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Prolonged Transgene Expression in Cotton Rat Lung with Recombinant Adenoviruses Defective in E2aHuman Gene Therapy, 1994